• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

Publication Library / Publications

Health-related quality of life and productivity/activity impairment in patients with transfusion-dependent B-thalassaemia in the UK NHS: Data from a UK Multicentre observational study

Objectives

Patients with the most severe form of β-thalassaemia require chronic red blood cell (RBC) transfusions to sustain life (transfusion-dependent β-thalassaemia [TDT]). Treatment with chronic RBC transfusions requires iron chelation therapy and monitoring to prevent complications. Our study aimed to describe the real-world management and patient-reported outcomes (PROs) of patients with TDT in the United Kingdom.

Methods

An observational study was conducted in 9 centres, comprising a retrospective chart-review and cross-sectional PRO questionnaires (completed at enrolment). Eligible patients had a documented diagnosis of TDT (≥8 transfusions during first year of chronic transfusion therapy or ≥100 mL/kg/year of packed RBCs) ≥2 years pre-data collection. Herein we report results from patients’ EuroQOL 5 dimension-3 level (EQ-5D-3L), child-friendly EQ-5D (EQ-5D-Y), Work Productivity and Activity Impairment (WPAI), and TranQoL questionnaires.

Results

Of 165 study patients, 120 completed ≥1 PRO(s) (median age 28.5 [range=8.4–67.4] years; 48% female). Mean EQ-5D-3L utility score (ages ≥16) was 0.69 (standard deviation [SD]=0.33; n=94); 57% (n=56/98) reported ‘moderate’/‘extreme’ pain, 52% (n=49/95) reported at least ‘some problems’ performing usual activities, and 42% (n=41/97) reported ‘some problems’ with mobility. Twenty patients completed the EQ-5D-Y (8–15 years), 50% reported ‘some’/’a lot’ of pain. Median WPAI domain scores were: absenteeism (3%, interquartile range [IQR]=0–17%, n=44), presenteeism (30%, IQR=10–60%, n=49), total work productivity loss (38%, IQR=23–60%, n=44) and activity impairment (50%, IQR=20–80%, n=88). Mean TranQoL total scores were 58.6 (SD=18.4, patients aged >18, n=94), and 74.8 (SD=15.0, patients aged 7–18 years, n=27); the most affected domain was ‘school and career health’ (mean 51.3 [SD=30.0], n=92).

Conclusions

Our results indicate that TDT has a substantial impact on patients’ health-related quality of life (affecting several domains including pain, usual activities, and mobility) and work productivity, with productivity/activity impairment appearing comparable to or higher than reported in other chronic conditions (e.g. COPD, rheumatoid arthritis; Miller, 2016).

Authors K Ryan, S Pancham, P Telfer, F Shah, J Kell, S Pollard, R Wynn, M Velangi, E Chalmers, J Hickey, C Paramore, M Jobanputra
Journal Value in Health
Therapeutic Area Hematology
Center of Excellence Real-world Evidence & Data Analytics
Year 2019
Read full article

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2025. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top